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In the last years, oncogene-driven lung cancer patients 
have witnessed an overwhelming progress in treatment 
options, especially in advanced setting of the disease (1). 
On the other hand, how to improve overall survival (OS) 
in epidermal growth factor receptor (EGFR)-positive 
(EGFR+) or ALK-rearranged early-stage lung cancer 
patients is unclear and whether tyrosine kinase inhibitors 
(TKI) play a role in the adjuvant setting is still matter of 
debate (2). Therefore, in this stage of non-small cell lung 
cancer (NSCLC), molecular analyses are not routinely 
performed. Different trials have been conducted involving 
EGFR+ early stage (I–IIIA) NSCLC patients, with the 
intent to demonstrate an improvement in patients’ disease-
free survival (DFS) and OS. The two first phase III trials in 
this setting, NCIC CTG BR19 and RADIANT, conducted 
before the validation of EGFR mutations’ predictive role 
and enrolling, thus, unselected patients (or enriched for 
EGFR gene amplification and protein expression), failed 
to demonstrate any relevant role of gefitinib and erlotinib, 
respectively (3,4). Since then, the classical chemotherapeutic 
approach (cisplatin-based) remained the gold standard 
treatment also for these patients.
Later on, two other trials, enrolling only Chinese 
patients, have been conducted testing an investigational 
approach versus cisplatin-vinorelbine control arm. The 
EVAN study, a phase II trial evaluating a small number of 
only IIIA stage patients, reported an increase in 3-year DFS 
of 54% for erlotinib-treated patients versus 20%. However, 
these results couldn’t be largely applied taking into account 
that IIIA stage is a high-risk population, Asian lung cancer 
patients retain particular clinic-pathological features, and 
the narrow number of participants weakened the results (5). 
The ADJUVANT/CTONG1104 phase III trial recently 
reported an improved median DFS of 28.7 months for 
gefitinib versus 18 months for chemotherapy. Even though 
these results shed light on the potential role of TKI as 
curative options for EGFR+ patients, DFS curves tend to 
converge at 36 months, denoting only a transient clinical 
benefit (6). Mature OS data will help the interpretation 
of study’s results, strengthening the role of adjuvant TKI, 
particularly for patients that will receive EGFR inhibitors 
again at relapse. OS data from ongoing ALCHEMIST and 
ADAURA clinical studies, evaluating, the first, erlotinib 
for 2 years versus clinical observation and, the latter, 
osimertinib versus placebo for 3 years in complete resected 
patients, will inform properly in terms of long-term survival 
benefit (7,8).
In this scenario, Pennell et al. recently published results 
of the SELECT trial (9). In the phase II single-arm clinical 
study patients, surgically-treated for a stage IA–IIIA 
EGFR-mutated NSCLC, received, after chemotherapy 
and radiotherapy, erlotinib at 150 mg/die for 2 years. 
With a total number of 100 patients, the primary end-
point of 2-year DFS has been met, reporting an 88% rate 
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compared to historical control of 76% (9). Median DFS 
and OS have not been reached and the estimated 5-year 
DFS and OS were 56% and 86%, respectively. Although 
around 70% of the patients concluded the entire course 
of 2 years treatment with erlotinib, a large number of 
patients (40%) required a first, and in a less extent a second 
dose reduction, due to clinically known erlotinib toxicities 
(i.e., rash, diarrhea, fatigue). Almost the entire number 
of patients experiencing a disease recurrence had stopped 
erlotinib, with a free disease interval of 25 months. These 
patients maintained EGFR canonical mutation at relapse, 
when a re-biopsy approach was feasible. The 65% of 
relapsed patients obtained a clinical benefit when erlotinib 
was re-administered for a medium period of 13 months, 
highlighting the feasibility of TKI re-treatment after 
adjuvant therapy.
Despite encouraging results of the SELECT study, 
some critical issues emerge. One major point concerns 
treatment-related toxicities, requiring multiple dose 
reductions (40% of patients) ,  in absence of solid 
randomized efficacy data of lower doses of erlotinib or 
therapy discontinuation (11% of the studied population). 
The cumulative toxicity of such a long treatment in a 
particular setting, as the adjuvant one, jeopardizes patients’ 
compliance and the achievement of effective dose intensity. 
Symptoms and quality of life monitoring, actually not 
investigated in the SELECT trial, acquires crucial value 
in this setting, in which financial costs and duration of 
adverse events during the whole timeframe of treatment 
(i.e., 24 months) are hardly comparable to those of the shorter 
standard chemotherapy strategy (3 months) (10). Moreover, 
the SELECT trial is a phase II single arm study without 
untreated control data and the population involved is 
heterogeneous (patients with resected stage IA to IIIA), 
including subjects at higher risk of disease recurrence 
(i.e., N1–N2) and patients for whom adjuvant therapy is 
not recommended in clinical practice (i.e., stage I) (11). 
Undoubtedly, more selected data are needed to better 
understand which patients actually would benefit the 
most from adjuvant targeted therapy. Moreover, lacking 
of OS data, that play a crucial role in the perspective of a 
treatment algorithm aimed at eliminating the microscopic 
residual disease, undermines study’s relevance. The 
median OS, in fact, is one of the secondary objectives and 
has not been reached yet. On the other hand, the primary 
endpoint—DFS—representing a surrogate measure of 
efficacy, is not affected by following treatment choices or 
by eventual crossover and seems to have, however, a quite 
right association with OS results in the adjuvant setting (12).
How long the treatment has to be protracted is another 
matter of debate. In the SELECT trial few recurrences 
(4%) occurred during targeted therapy, whereas a major 
rate was found in patients that interrupted it precociously. 
Thirty-six of the 40 patients with recurrent cancer had 
completed erlotinib treatment, and most of them were 
sensitive to the re-challenge with the TKI. These data seem 
to support the feasibility of a standard sequential treatment 
approach at time of relapse (13). The biological mechanism 
underpinning this disease behavior is not perfectly 
understood; it seems that cancer proliferation, suppressed 
by the TKI, arises again when the treatment is suspended. 
The most supported hypothesis is that targeted therapies 
are able to inhibit cancer growth during their administration 
but are inefficient to eradicate the microscopic disease. In 
this scenario, the evaluation of the minimal residual disease 
could guide the identification of patients who really benefit 
of targeted therapy in the adjuvant setting and patients who 
would receive more advantages from a targeted treatment 
at relapse (14). Moreover, it could help to define how 
long should be extended the adjuvant treatment in order 
to maximize the long-term impact. Lastly, understanding 
the right balance between different treatments’ impacts 
on the disease—chemotherapy and radiotherapy, with 
their eradicative and immunogenic roles, and TKIs with 
their growth-suppressing properties—could help to find 
a strategy to improve clinical outcome and identify early 
mechanisms of resistance. 
It is noteworthy that osimertinib turned out to be widely 
superior to first generation TKIs among EGFR+ patients in 
the advanced setting, making SELECT results potentially 
outdated (15). Relevant information about the type of 
adjuvant TKI and the correct duration (in terms of years) 
will derive from ongoing trials, such as ALCHEMIST and 
ADAURA. Furthermore, a change in this direction would 
revolutionize the diagnostic approach to NSCLC patients, 
expanding the molecular characterization to the early stage 
disease, currently not recommended in clinical practice (11).
Nevertheless, several positive considerations are due. The 
2-year DFS of 88% is an important result that overtakes 
historical data in this setting (16). The combination 
of chemotherapy, radiotherapy if indicated, and TKIs 
and their potential synergistic effect could represent a 
potential future therapeutic alternative in postoperative 
management. TKI-restricted strategy, however, represents a 
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promising option, particularly for patients unfit for standard 
chemotherapeutic regimen, expanding, in this way, the 
population eligible for adjuvant therapy. In the coming 
years, due to increasing data supporting the utilization of 
screening procedures, the percentage of early stage NSCLC 
patients could rise and new personalized and efficient 
strategies are needed. More solid data on the potential 
predictive role of EGFR mutation in the precocious setting 
represent a crucial prerequisite for further developments in 
this direction. Even if deeper analyses are essential, these 
studies, such as the SELECT trial, provide new precious 
information in the adjuvant setting, paving the way toward 
a more effective postoperative treatment strategy for every 
single patient affected by NSCLC. The availability of more 
potent and well-tolerated inhibitors and the opportunity to 
molecularly sub-stratify even oncogene-addicted patients 
(e.g., high-risk with EGFR+/TP53+ lung cancers) could 
represent a relevant chance to address the best treatment to 
the right patient, not only delaying disease recurrence but 
also altering its natural history.
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